Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
4.010
-0.170 (-4.07%)
At close: Nov 7, 2025, 4:00 PM EST
4.050
+0.040 (1.00%)
After-hours: Nov 7, 2025, 7:59 PM EST
Inventiva Revenue
Inventiva had revenue of 5.61M EUR in the half year ending June 30, 2025, a decrease of -15.28%. This brings the company's revenue in the last twelve months to 16.97M, down -10.36% year-over-year. In the year 2024, Inventiva had annual revenue of 14.09M, down -38.24%.
Revenue (ttm)
16.97M EUR
Revenue Growth
-10.36%
P/S Ratio
28.70
Revenue / Employee
143,814 EUR
Employees
118
Market Cap
572.01M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IVA News
- 24 days ago - Inventiva Announces the Implementation of a New ATM Program - GlobeNewsWire
- 4 weeks ago - Inventiva S.A. (IVA) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 5 weeks ago - Inventiva Appoints Andrew Obenshain as Chief Executive Officer - GlobeNewsWire
- 5 weeks ago - Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 5 weeks ago - Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update - GlobeNewsWire
- 5 weeks ago - Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings - Benzinga
- 6 weeks ago - Inventiva to Host Analyst and Investor Event on October 8, 2025 - GlobeNewsWire